INO Inovio Pharmaceuticals, Inc.

NASDAQ
$1.09

Inovio Pharmaceuticals, Inc. (INO) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +34.6% since its last earnings release on August 12, 2026.

Inovio Pharmaceuticals Beat Consensus Estimates
Wednesday, August 12, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.20)
Rev est $2M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.99

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

Sector

Healthcare

Industry

Biotechnology